CNTB Connect Biopharma Holdings Ltd
Company Analysis
Latest News
🔴 Connect Biopharma is trading 7.3% down with no clear company-specific catalyst
Connect Biopharma is trading 7.3% down at $0.74 on October 22, 2026, with no clear cause identified. - The latest identified company news was positive...
🟢 Connect Biopharma is trading 10% up in pre-market amid biotech-sector strength
Connect Biopharma is trading at $0.87, up 9.51%, with biotech-sector strength the likeliest available explanation. - Supplied sector context reports XBI up...
🔴 Connect Biopharma is trading 6.3% down on October 21, 2026 — no company-specific catalyst identified
Connect Biopharma is trading at $0.82, down -6.30%, during the October 21 session; no company-specific announcement explaining the decline was found in...
🟢 Connect Biopharma is trading 5.8% up
Connect Biopharma is trading at $0.92, up 5.76% in live trading on October 12, 2026; the reason for the gain remains unclear. - No clear company-specific...
🟢 Connect Biopharma is trading 7.7% up in pre-market as the reason for the rise remains unclear
Connect Biopharma is trading 7.7% higher at $0.94 before the market opens on October 12, with the reason for the rise unclear. - The October 9 closing price...
🟢 Connect Biopharma is trading 5% up as biotech stocks rally
Connect Biopharma is trading 5.01% higher at $0.92 on October 9, 2026, in line with a biotech-sector rally. - Biotech is rallying, with XBI up 2.50%, amid...
🔴 Connect Biopharma is trading 5% down today amid biotech-sector weakness
Connect Biopharma is trading at $0.90, down 5.11%, amid biotech-sector and broader risk-off pressure. - No new company-specific announcement explaining the...
🟢 Connect Biopharma is trading 6% up; immediate catalyst remains unclear
Connect Biopharma is trading 6.02% higher at $0.96, but the immediate catalyst remains unclear. - No new company-specific announcement explaining the October...
🟢 Connect Biopharma is trading 6.6% up
Connect Biopharma is trading 6.57% up at $0.96 on October 6; the immediate driver remains unclear. - Its latest announced catalyst was positive preliminary...
🔴 Connect Biopharma is trading 5% down with no clear catalyst identified
Connect Biopharma is trading at $0.93, down 5.06%, on October 2, 2026, with no verified company-specific announcement explaining the decline. - The latest...
🟢 Connect Biopharma is trading 8.71% up today — no verified catalyst identified
Connect Biopharma is trading 8.71% higher at $1.06, with no October 2 company announcement or verified catalyst identified. - The latest company press release...
🔴 Connect Biopharma is trading 10.2% down
Connect Biopharma is trading at $0.99, down 10.24%, with no confirmed catalyst identified for the October 1 decline. - A report cited negative sentiment around...
🔴 Connect Biopharma is trading 5% down
Connect Biopharma is trading at $1.04, down 5.00%, with no confirmed explanation for the decline. - No confirmed October 1 company announcement or source...
🔴 Connect Biopharma is trading 6.35% down in pre-market
Connect Biopharma is trading 6.35% down at $1.03 in pre-market, with no confirmed overnight announcement explaining the decline. - On September 30, the...
🟢 Connect Biopharma is trading 5.5% up in after-hours trading as COPD trial cut failures by 81%
Connect Biopharma is trading $1.16 (+5.45%) after positive preliminary Phase 2 results showed rademikibart reduced COPD treatment failure by 81% through Week 4...
Connect Biopharma's COPD Drug Just Delivered Blockbuster Data — But Can a $110 Million Company Compete in a Market Dupixent Already Owns?
Shares of Connect Biopharma surged 75% to $1.74 on September 30 after the tiny San Diego biotech reported that its experimental drug slashed treatment failures...
🟢 Connect Biopharma is trading 75% up today after Phase 2 trial cut failures 81% versus placebo
Connect Biopharma is trading 75.40% up at $1.74 after positive topline results announced September 30, 2026, from its Phase 2 COPD study of rademikibart. -...
Connect Biopharma Reports Positive Phase 2 Data for COPD Treatment Rademikibart
Connect Biopharma (CNTB) announced positive topline results from its global Phase 2 study of rademikibart, an antibody treatment for acute exacerbations in...
🟢 Connect Biopharma is trading 23.84% up in pre-market — no company-specific catalyst identified
Connect Biopharma is trading 23.84% up in pre-market at $1.23 on September 30, with no company-specific announcement identified to explain the move. - The...
🟢 Connect Biopharma is trading 9% up in pre-market with no company-specific explanation identified
Connect Biopharma is trading 8.86% higher at $1.08 before the September 30, 2026 open, with no company-specific announcement identified to explain the move. -...